Although the study did not define PARP1 function, PAR binding to hnRNPs causes the dissociation of hnRNPs from RNA, which suggests a reduction of hnRNP noncovalent binding with PAR, via the administration of a PARP inhibitor, can increase the amount of unmodified hnRNPs and may improve treatment for some neurodegenerative diseases [69,72] (Figure 2d). This evidence concerns the gene PARP1 and neurodegenerative disease.